Takeaway
- In patients with type 2 diabetes (T2D), once-weekly semaglutide 0.5 mg and 1.0 mg significantly improved glycated haemoglobin (HbA1c) level and body weight, with a similar tolerability profile, regardless of whether they receive background metformin (MET) or MET plus sulphonylurea (SU).
Why this matters
- Findings support health care professionals in providing optimal care with glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the basis of their background oral antidiabetic drugs (OADs) in patients with T2D.
Study design
- A post hoc analysis of data from the SUSTAIN 2, 3, 4 and 10 trials included 3411 patients with T2D (3410 in the safety analysis).
- Change in HbA1c level and body weight at the end of treatment visit (at 30 weeks for SUSTAIN 4 and 10 and at 56 weeks for SUSTAIN 2 and 3) and rates of hypoglycaemia and adverse events (AEs) were evaluated.
- Funding: Novo Nordisk A/S.
Key results
- Across 4 trials:
- Semaglutide significantly reduced HbA1c (estimated treatment difference [ETD], −0.32 to −0.79%-points for 0.5 mg, and −0.38 to −1.07%-points for 1.0 mg vs comparators; P<.01) in patients who received both MET and MET plus SU.
- Semaglutide was associated with a significant reduction in body weight (ETD, −2.35 to −4.72 kg for 0.5 mg, and −2.96 to −6.76 kg for 1.0 mg vs comparators; P<.0001) irrespective of the background OAD therapy.
- Hypoglycaemic events were more frequent in patients who received background MET plus SU vs those who received MET alone, regardless of whether they received semaglutide or a comparator.
- Rate of AEs leading to premature treatment discontinuations in patients treated with semaglutide were consistent irrespective of the background OAD therapy.
Limitations
- Post hoc analysis.
References
References
